PATIENT STATS
| AGE | PSA AT | FOLLOW-UP | % PSA | PERIOD OF | GLEASON | CLINICAL | PATHOLOGIC | IPSS-INDEX | IPSS | EPS | EPS |
| DIAGNOSIS | PSA | DECREASE | SURVEILLANCE | SCORE | STAGE | STAGE | CHANGE | CHANGE | |||
| 61 | 8.5 ng/ml | 2.9 ng/ml | 66% | 64 months | 5 (3+2) | T2c | T2c | 5.5-2.5 = 3 | 55% | 256-113 | 56% |
| 68 | 7.0 ng/ml | 2.8 ng/ml | 60% | 60 months | 5 (3+2) | T1c | T2a | 17.5-8.5 = 11 | 56% | 85-15 | 82% |
| 43 | 4.7 ng/ml | 2.1 ng/ml | 55% | 30 months | 6 (3+3) | T1c | T2a | 4-0 = 4 | 100% | 325-190 | 42% |
| 65 | 11.7 ng/ml | 7.6 ng/ml | 35% | 38 months | 5(3+2)/6(3+3) | T1c | T2b | ||||
| 64 | 2.9 ng/ml | 1.5 ng/ml | 48% | 60 months | 6 (3+3) | T1c | T2a | ||||
| 55 | 2.1 ng/ml | 3.0 ng/ml | +43% | 34 months | 5 (3+2) | T2c | T2c | 6.5-2 = 4.5 | 69% | 350-158 | 55% |
| 56 | 7.3 ng/ml | 4.2 ng/ml | 42% | 33 months | 5(2+3)/6(3+3) | T2a | T2b | 10.5-6 = 4.5 | 43% | TNTC-5 | 99% |
| 70 | 6.9 ng/ml | 5.1 ng/ml | 26% | 19 months | 6 (3+3) | T2c | T2a | 11.5-7.5 = 4 | 35% | 268-17 | 94% |
| 68 | 5.8 ng/ml | 4.9 ng/ml | 16% | 31 months | 6 (3+3) | T1c | T2a | 4-0 = 4 | 100% | ||
| 56 | 9.1 ng/ml | 4.9 ng/ml | 46% | 47 months | 6 (3+3) | T1c | T2a | 11-7 = 4 | 36% | 375-150 | 60% |
| 61 | 3.0 ng/ml | 0.8 ng/ml | 73% | 24 months | 5 (3+2) | T1c | T2a | ||||
| 48 | 3.2 ng/ml | 2.2 ng/ml | 31% | 13 months | 6 (3+3) | T2a | T2b | 9.5-2 = 7.5 | 79% | ||
| 69 | 6.2 ng/ml | 3.2 ng/ml | 48% | 10 months | 5 (3+2) | T1c | T1a | ||||
| 56 | 4.4 ng/ml | 1.9 ng/ml | 57% | 24 months | 6(3+3)/7(3+4) | T2c | T2c | 8.5-1.5 = 7 | 82% | 350-30 | 91% |
| 74 | 11.4 ng/ml | 10.9 ng/ml | 13% | 28 months | 6 (3+3) | T2b | T2b | ||||
| 63 | 6.8 ng/ml | 1.9 ng/ml | 72% | 33 months | 5 (3+2) | T1c | T2a | 5.5-2.5 = 3 | 55% | 275-70 | 75% |
| 71 | 6.6 ng/ml | 4.7 ng/ml | 29% | 12 months | 6 (3+3) | T1c | T2c | ||||
| 64 | 14.4 ng/ml | 1.9 ng/ml | 87% | 14 months | 6 (3+3) | T1c | T2a | ||||
| 70 | 8.4 ng/ml | 3.0 ng/ml | 64% | 5 months | 6 (3+3) | T1c | T2a | ||||
| 72 | 4.4 ng/ml | 5.0 ng/ml | +14% | 11 months | 6(3+3)/7(3+4) | T2b | T2c | ||||
| TOTALS: | 134.8 ng/ml | 60.3 ng/ml | 802 | 588 | |||||||
| Mean | Mean PSA | Mean % | Mean | Mean % | Mean % | ||||||
| Starting PSA | Change | Decrease | Months | Change | Change | ||||||
| 6.7 ng/ml | 3.0 ng/ml | 40% | 30 | 65% | 73% | ||||||
|
EPS =Expressed Prostatic Secretion (An Indication of Prostate Inflammation) |
|||||||||||
|
PSA = Prostate Specific Antigen |
|||||||||||
|
IPSS-Index = International Prostate Symptom Score |
|||||||||||
|
TNTC = Too Numerous to Count |
|||||||||||
|
Gleason Score: 2-10 (Primary Cancer Grade + Secondary Cancer Grade) with 2 being the most favorable and 10 being the worst |
|||||||||||
